Executive Director Jonathan Agin recently traveled to Seattle, Washington from June 12-14th to attend the annual meeting of the Coalition Against Childhood Cancer, also known as CAC2. CAC2 began to take shape in 2011 to bring many different stakeholders from the childhood cancer community together to collectively raise awareness, create collaborative efforts among member organizations and reduce duplication. Max Cure immediately saw the benefit of joining in this endeavor and today stands with close to 100 other childhood cancer related organizations and individual advocates working toward the same fight against childhood cancer.
During the meeting, members interact with some of the world’s top clinicians and researchers, members of the National Cancer Institute, FDA and the pharmaceutical industry to learn about new developments and how our collective work is impacting children with cancer. Additionally, there are specific meetings of separate interest groups such as research, advocacy and family support to name a few. Whereas Max Cure’s mission aligns with all of the interest groups, we have been most active with our participation in the research group. Since 2017 when Jonathan embarked upon reshaping Max Cure’s research direction through a bold and aggressive path, our participation in collaborative groups like the CAC2 research interest group have allowed us to further ensure that Max Cure’s research funding is laser focused. By helping to shape priorities used for collaboration by member organizations, we gain insight into how best to make research-funding decisions as well as create meaningful partnerships to accelerate results.
As part of Max Cure’s research efforts and participation in CAC2, we recently joined the International Cancer Research Partnership (ICRP). Through the ICRP, we are better able to determine that our research dollars are not duplicating other projects that are already well funded.
The Max Cure Foundation has always held the belief that through collaboration we can achieve greater results as a community. We feel strongly that our participation in groups like CAC2 provide the platform for our work to reach more support and create faster results as we continue to fight childhood cancer.
Executive Director Jonathan Agin Provides Public Comment Before the Food and Drug Administration
On June 20, 2018, Executive Director Jonathan Agin provided open public comments before the Food and Drug Administration (FDA) Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee on the issue of the implementation of the RACE for Children Act signed into law in August 2017. (more…)
The Max Cure Foundation’s advocacy efforts round out our three-prong mission and sometimes place members of our executive team at the forefront of the childhood cancer community on certain issues. The pending legislation emotionally labeled as the Right to Try law that has been a string of individual bills introduced in Congress, and already the law in some states, is one such example of how Max Cure’s advocacy efforts are aimed at working to help children with cancer. (more…)
Max Cure’s Executive Director Jonathan Agin is featured in Real Clear Health. “As the Executive Director of the Max Cure Foundation, I am no longer fighting for my daughter and her life. What I am doing—and what so many of us in the childhood cancer community are doing—is fighting for the lives of all of children suffering.” (more…)
Introduction by Jonathan Agin, JD, Executive Director
As a childhood cancer nonprofit organization, the Max Cure Foundation (MCF) continually engages in the fight against this complex disease on multiple fronts. Since MCF’s inception, we have collectively funded over $960,000 for research purposes. Our team through, Richard Plotkin and Jonathan Agin, have effectively been engaged in working in Washington, DC to advocate for legislative and regulatory change. And finally, but certainly one of our most important charges, is our family assistance program known as Roar Beyond Barriers (RBB). (more…)
On June 29, 2016, I was one of five individuals selected to present public comments at the Federal Drug Administration (FDA) pedODAC meeting in a special session dedicated to the pediatric brain tumor that took my daughter’s life, (DIPG). (more…)
As American shopping shifts from the brick-and-mortar stores to online retail, and even groceries have innovated for 21st Century consumers, agencies such as the USDA should reconsider how to best serve their constituents under their WIC and SNAP programs. (more…)
On September 12, 1962 President Kennedy delivered his famous “moonshot” speech. Declaring that as a nation, we would focus vast resources to landing a man on the moon and safely bringing that man back to earth. (more…)
On October 28, 2015, Richard Plotkin appeared as a panelist at a two-day colloquium at New York Academy of Science sponsored by NYU School of Medicine, NYU Langone Medical Center, and Johnson & Johnson. The subject of the program is identified as, “Pre-Approval Access: Can Compassion, Business, and Medicine Coexist?” (more…)